Therapeutic trial & Research projects
THERAPEUTIC TRIALS
- Title: Randomized open label study to compare the efficacy and safety of everolimus followed by chemotherapy with STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by everolimus upon progression, in advanced progressive pNETs (SEQTOR)
Status: ongoing
- Title: Trial to assess the efficacy of lenvatinib in metastatic neuroendocrine tumors (TALENT)
Status: ongoing
- Title: Efficacy and safety of lanreotide autogel® 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours having progressed radiologically while previously treated with lanreotide autogel® 120 mg administered every 28 days (CLARINET FORTE)
Status: ongoing –
- Title: Efficacy and safety of lanreotide autogel 120 mg in combination with temozolomide in subjects with progressive well differentiated thoracic neuroendocrine tumors. A pilot phase II study (ATLANT)
Status: ongoing -
- Title: First International Randomized Study in MAlignant Progressive Pheochromocytoma and Paraganglioma (FIRSTMAPP)
Status: ongoing –
- Title: Efficacy of lanreotide in patients with Multiple Endocrine Neoplasia type 1 (MEN1) with progressive duodenum-pancreatic neuroendocrine (LAN in MEN1 vs FOLLOW UP)
Status: ongoing
- Title: Phase II trial to evaluate the efficacy and safety of Temozolomide in second-line in patients with Neuroendocrine Tumor of pancreatic , gastrointestinal or pulmonary origing progressing after prior first line chemotherapy platinum-based (TENEC)
Status: ongoing
- Title: A Phase II Single Arm Trial Evaluating the Clinical impact of Octreotide LAR in the induction of immunologic response in patient with Neuroendocrine Tumors ( IMMUNeOCT)
Status: under evaluation
- Title: An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoracic origin who have progressed on prior treatment . (Oncology Clinical Protocol CPDR001E2201)
Status: under evaluation
- Title: Multicenter 3-arm trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymus – (LUNA)
Status: closed
- Title: A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin – (RADIANT-4)
Status: closed
- Title: Open label extension study of Lanreotide Autogel 120 mg in patients with non functioning entero pancreatic endocrine tumour (CLARINET - OLE)
Status: closed
- Title: Sicurezza del trattamento con lanreotide ad alte dosi in pazienti affetti da tumori neuroendocrini scarsamente responsivi al trattamento con analoghi della somatostatina a dosi standard (LAN HD)
Status: closed
- Title: Mono centre, open label proof of concept study SOM230 in progressive medullary thyroid cancer patients and the combination with RAD001 upon progression (SOM RAD)
Status: closed
RESEARCH PROJECTS:
- Title: Cytokines as predictive factors of response to SSA treatment in neuroendocrine tumour patients (SSA CYTOKINES)
Status: ongoing
- Title: Therapeutic sequence in patients with neuroendocrine tumors (NET): an observational, multicentre, retrospective study (ELIOS STUDY)
Status: ongoing
- Title: Antigenic targets for immunotherapy of MEN1-associated pancreatic neuroendocrine tumors (pNETs)
Status: ongoing